QPPV.COM KNOWLEDGE ASSESSMENT

Galcanezumab: Classification, History, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Galcanezumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which product information is most important to preserve when investigating a possible quality-related event involving Galcanezumab?

Only the patient's age and sex Presentation, batch, expiry, storage, preparation and administration-system details Only the preferred term selected for the event Only the date of the patient's next migraine episode

Question 2 of 10 A report labels an event as 'treatment failure' without describing disease measurements, adherence or interruptions. What is the main pharmacovigilance concern?

The label is sufficient because treatment failure is self-evident The assessment lacks evidence needed to distinguish true lack of effect from adherence, scheduling, disease variability or switching factors Treatment failure should always be coded as an adverse drug reaction Only laboratory data are relevant to lack of effect

Question 3 of 10 Why can an interruption of Galcanezumab treatment be difficult to interpret as a complete dechallenge?

The product is not biologically active after administration The biological effect may persist after treatment is held, so lack of immediate improvement or recurrence may not be straightforward Dechallenge is only valid for small molecules An interruption always proves that the event was unrelated

Question 4 of 10 Which follow-up information would be most useful for assessing a serious or opportunistic infection reported with Galcanezumab?

Only the patient's preferred injection site Site, organism, cultures, imaging, antimicrobial treatment, immune status and outcome Only the number of migraine attacks before treatment Only whether the event was coded as serious

Question 5 of 10 Why is the distinction between a CGRP ligand-directed antibody and a CGRP receptor antagonist relevant to pharmacovigilance?

It determines whether the product must be administered orally It identifies the precise biological target and helps frame plausible effects and differential diagnoses It proves that any vascular event is caused by the product It eliminates the need to collect information on concomitant medicines

Question 6 of 10 Which description best captures Galcanezumab's pharmacological classification?

A small-molecule antagonist that directly blocks the CGRP receptor A humanised IgG4 monoclonal antibody directed against the CGRP ligand A nonspecific immunostimulant that activates multiple inflammatory pathways A recombinant enzyme that degrades CGRP receptors

Question 7 of 10 Which statement best reflects the regulatory relevance of regional product information for Galcanezumab?

A single global label always determines indication, dose and warnings everywhere Current regional product information controls the applicable authorised context, while requirements may vary by jurisdiction Regional differences matter only for commercial activities Operational recommendations in an article automatically become legal requirements

Question 8 of 10 Which statement best describes the intended pharmacological effect of Galcanezumab?

It increases CGRP signalling to restore vascular tone It binds CGRP and reduces its ability to activate CGRP receptors involved in migraine biology It permanently removes CGRP-producing neurons It blocks all immune-cell signalling throughout the body

Question 9 of 10 Which governance evidence would best demonstrate that a pharmacovigilance system is functioning effectively for Galcanezumab?

A procedure exists, but there is no evidence that follow-up was performed Records showing targeted follow-up, medical assessment, signal review, reconciliation and documented escalation decisions A database containing only final seriousness classifications A product label without supporting case-processing documentation

Question 10 of 10 Which statement best describes how host susceptibility fits into the safety assessment of Galcanezumab?

Host factors are irrelevant once a plausible mechanism has been identified Age, infection history, immune status, organ reserve and comorbidity can modify risk and interpretation Host factors determine the product's molecular class Host factors should be collected only for product-quality complaints

QPPV.com

Galcanezumab: Classification, History, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Cookie Settings